Almac encourages oncology collaboration between US and Northern Ireland
Almac highlights oncology hub in Northern Ireland and expertise in personalised medicine
Declan Kelly, US Economic Envoy to Northern Ireland, opened the event.
Arlene Foster, Minister for the Department of Enterprise Trade and Investment, spoke on ‘Setting the Northern Ireland Context’, while Dr John Niederhuber, director of the National Cancer Institute (NCI) highlighted the relationship between the NCI and Northern Ireland.
The ‘oncology hub’, a collaboration between academia and the pharmaceutical industry in Northern Ireland, is seeking to share its expertise and expand its links with the international and US-based pharmaceutical, biotech and diagnostic industries, in addition to academic and clinical research centres.
Almac, working with Queen’s University Belfast, aims to increase r&d in personalised medicine by acting as the bridge between academia and industry.
‘Raising the oncology hub’s profile among senior decision makers and Government officials will help ensure that appropriate support reaches this commendable initiative, which is constantly striving to break new ground and foster further innovation in personalised medicine,’ said Alan Armstrong, chief executive of Almac.
You may also like
Research & Development
Why the strategic benefits of outsourcing formulation development matter
The formulation development outsourcing market continues to grow at pace as pharmaceutical companies experience first-hand the strategic advantages that a solid partnership has in terms of driving resource optimisation, accelerating time to market and enhancing competitive advantage
